Serenex
Pioneering innovative treatments in oncology and beyond through a robust Hsp90 inhibitor platform and advanced therapy for oral mucositis.
Pioneering innovative treatments in oncology and beyond through a robust Hsp90 inhibitor platform and advanced therapy for oral mucositis.
Serenex is a biotechnology and healthcare company that has been pioneering innovative treatments in oncology and beyond since its founding in 2000. Specializing in medical drug discovery and development, Serenex focuses on an Hsp90 product platform, offering a range of small molecule Hsp90 inhibitors for various conditions, including cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative conditions such as Alzheimer's. One of its notable developments is SNX-1012, a treatment for oral mucositis in patients with solid tumors. In 28 June 2007, Serenex received a significant $26.00M Series D investment from Intersouth Partners, Pac-Link, Lilly Ventures, Takeda Pharma, Seaflower Ventures, Pearl Street Venture Funds, L. P., Cornel Capital Partners, Mediphase Venture Partners, and Mitsubishi International Corporation (MIC). The company's dedication to cutting-edge medical advancements in oncology and its successful acquisition by Pfizer in 2008, reflect its potential and the recognition it has garnered from industry leaders.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series D | $26.00M | 9 |
|
28 Jun 2007 |
| Series C | $30.00M | 1 |
|
06 Oct 2005 |
| Venture Round | $8.00M | - | 30 Jul 2004 | |
| Series B | $15.00M | - | 20 Aug 2002 | |
| Series A | $2.00M | - | 01 Jun 2001 |
No recent news or press coverage available for Serenex.
We care about your data, and we'd love to use cookies make your experience better.
